PHARMACOGENETICS OF ANTITHROMBOTIC DRUGS: STATUS UPDATE ON THE PROBLEM-Reference-Cited by-同舟云学术

PHARMACOGENETICS OF ANTITHROMBOTIC DRUGS: STATUS UPDATE ON THE PROBLEM

Published:2018-12-27 Issue:2 Volume: Page:115-129
ISSN:2658-5952
Container-title:Atherothrombosis Journal
language:
Short-container-title:Aterotromboz

Author:

Kropacheva Ekaterina S.¹

Affiliation:

1. Myasnikov Clinical Cardiology Institute, Federal State Budgetary Institution “National Medical Research Center of Cardiology” of the Ministry of Health of the Russian Federation

Abstract

The review deals with the main trials devoted to the study of genetic markers of individual variability in drug response to antithrombotic agents. The first part describes the studies of the genes encoding the platelet receptor subunits studied in the association of the possible insufficient effect of acetylsalicylic acid, and transporter proteins and allelic variants with reduced CYP450 functional activity, which are associated with insufficient effect on clopidogrel therapy. The second part considers polymorphisms that determine the individual dose and the risk of bleeding due to excessive hypocoagulation in patients taking warfarin. It also presents current data on the study of genetically determined individual reactions to the new inhibitors: P2Y12 inhibitors (prasugrel and ticagrelor) and direct oral anticoagulants.

Publisher

Remedium, Ltd.

Reference87 articles.

1. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with st-segment elevation: the task Force for the management of acute myocardial infarction in patients presenting with st-segment elevation of the european society of Cardiology (ESC). European Heart Journal, 2018 January 7; 39 (Issue 2): 119–177.

2. ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task Force for dual antiplatelet therapy in coronary artery disease of the european society of Cardiology (ESC) and of the european Association for Cardio-thoracic surgery (EACTS). European Heart Journal, 2018 January 14; 39(Issue 3): 213–260.

3. Diagnostika i lechenie Fibrillyatsii predserdii. Rekomendatsii RKO, VNOA i ASSKh, 2012. 112 s./

4. Antithrombotic therapy and Prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 suppl): e637s–68s. doi:10.1378/chest.11-2306. pmid:22315274.

5. Sychev D.A. Rekomendatsii po primeneniyu farmakogeneticheskogo testirovaniya v klinicheskoi praktike. Kachestvennaya klinicheskaya praktika. 2001; 1: 3-10 [Sychev D.A. Guidelines for pharmacogenetic testing in clinical practice. Kachestvennaya Klinicheskaya Praktika. 2001; 1: 3-10.] (In Russ).

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Frequency of CYP2C19, P2RY12, ITGB3, ITGA2, and eNOS3 gene polymorphism in patients with myocardial infarction;Proceedings of the National Academy of Sciences of Belarus, Medical series;2024-05-27

2. Association of polymorphic variants of CYP2C19, P2RY12, ITGB3, ITGA2 and eNOS3 genes with high residual platelet reactivity while taking clopidogrel and acetylsalicylic acid at different terms of myocardial infarction;Rational Pharmacotherapy in Cardiology;2023-07-27

3. Prospects for personalized rehabilitative medicine;Bulletin Physiology and Pathology of Respiration;2021-04-02